PARP1 and Parkinson disease: More importantly, PARP1 activation promotes amyloid aggregation and toxicity, while PARP1 inhibition can significantly alleviate the disease symptoms in PD, as well as other neurodegenerative disease models [19,38], indicating that the downregulation of the response to DNA damage may be beneficial.